Metagenomi, Ebitda from 2010 to 2024

MGX Stock   2.02  0.01  0.50%   
Metagenomi, Common EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about -52.9 M in 2024. During the period from 2010 to 2024, Metagenomi, Common EBITDA regression line of annual values had significance of  0.0009 and arithmetic mean of (28,457,050). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-50.4 M
Current Value
-52.9 M
Quarterly Volatility
13.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Metagenomi, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Metagenomi, Common's main balance sheet or income statement drivers, such as Tax Provision of 9.7 M, Net Interest Income of 18.7 M or Interest Income of 18.7 M, as well as many indicators such as Price To Sales Ratio of 8.21, Dividend Yield of 0.0 or Days Sales Outstanding of 18.99. Metagenomi, financial statements analysis is a perfect complement when working with Metagenomi, Common Valuation or Volatility modules.
  
Check out the analysis of Metagenomi, Common Correlation against competitors.

Latest Metagenomi, Common's Ebitda Growth Pattern

Below is the plot of the Ebitda of Metagenomi, Common Stock over the last few years. It is Metagenomi, Common's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Metagenomi, Common's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Metagenomi, Ebitda Regression Statistics

Arithmetic Mean(28,457,050)
Coefficient Of Variation(47.98)
Mean Deviation11,299,273
Median(20,753,000)
Standard Deviation13,652,939
Sample Variance186.4T
Range35.3M
R-Value(0.76)
Mean Square Error83.5T
R-Squared0.58
Significance0.0009
Slope(2,333,583)
Total Sum of Squares2609.6T

Metagenomi, Ebitda History

2024-52.9 M
2023-50.4 M
2022-56 M
2021-39.2 M

About Metagenomi, Common Financial Statements

Metagenomi, Common investors use historical fundamental indicators, such as Metagenomi, Common's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Metagenomi, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-50.4 M-52.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Metagenomi, Stock Analysis

When running Metagenomi, Common's price analysis, check to measure Metagenomi, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Metagenomi, Common is operating at the current time. Most of Metagenomi, Common's value examination focuses on studying past and present price action to predict the probability of Metagenomi, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Metagenomi, Common's price. Additionally, you may evaluate how the addition of Metagenomi, Common to your portfolios can decrease your overall portfolio volatility.